RegeneRx Biopharmaceuticals Inc RGRX
$0.00
Last Updated: Aug 17, 12:00 AM·OOTC
Pricing for US stocks is delayed by 24 hours
RegeneRx Biopharmaceuticals Inc. Stock Analysis RGRX
United States Health Care Nano Cap RegeneRx Biopharmaceuticals, Inc. engages in the development of a novel therapeutic peptide, Thymosin beta 4 for tissue and organ protection, repair, and regeneration. The company is headquartered in Glen Echo, Maryland and currently employs 2 full-time employees. The firm has formulated TB4 into three distinct product candidates in clinical development: RGN-259, RGN-352 and RGN-137. RGN-259 is a preservative-free topical eye drop for regeneration of corneal tissues damaged by injury, disease or other pathology. RGN-259 is in phase three clinical trials in the United States and EU for the treatment of neurotrophic keratitis, an orphan indication. RGN-352 is an injectable formulation to treat cardiovascular diseases, central and peripheral nervous system diseases, organ damage associated with COVID-19, and other medical indications that may be treated by systemic administration. RGN-137 is a topical gel for dermal wounds and reduction of scar tissue. The company has active partnerships in four territories: North America, Europe, China and Pan Asia.
RegeneRx Biopharmaceuticals Inc (RGRX) Chart
Financial Metrics & Statements of RegeneRx Biopharmaceuticals Inc (RGRX)
FAQ's for RegeneRx Biopharmaceuticals Inc (RGRX)
- As of August 2026, RegeneRx Biopharmaceuticals Inc RGRX is classified as not covered according to Musaffa’s Shariah screening methodology. This classification is based on an assessment of the company’s business activities and financial ratios against Islamic investment guidelines.
- A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes RegeneRx Biopharmaceuticals Inc using these criteria to determine its compliance status.
- Muslim investors may consider investing in RegeneRx Biopharmaceuticals Inc if it meets Shariah compliance standards. Investors typically review the company’s business activities, debt levels, and non-permissible income before making a decision.
- Musaffa determines the Shariah status of RegeneRx Biopharmaceuticals Inc by analyzing whether the company’s core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.
- The Shariah compliance status of RegeneRx Biopharmaceuticals Inc may be updated periodically when new financial statements, earnings reports, or business activity information become available.
- Yes. A stock that is currently Shariah-compliant may become non-compliant if the company’s financial ratios exceed Shariah thresholds or its business activities change.
- You can check the latest Shariah compliance status of RegeneRx Biopharmaceuticals Inc on Musaffa’s stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.
Alternate Halal Stocks for RegeneRx Biopharmaceuticals Inc (RGRX)
Related Halal Stocks are Shariah-compliant companies that align with Islamic investment principles, avoiding prohibited industries like alcohol, gambling, and interest-based finance.
